Functions of TAp63 and p53 in restraining the development of metastatic cancer

Oncogene

Volumn 33, Issue 25, 2014, Pages 3325-3333

  Tan, E H ^a   Morton, J P ^a   Timpson, P ^a,b   Tucci, P ^c,d   Melino, G ^c,e   Flores, E R ^f   Sansom, O J ^a   Vousden, K H ^a   Muller, P A J ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF CALABRIA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

metastasis; mutant p53; p63; pancreatic tumours; PDAC

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; PROTEIN P63;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; METASTASIS POTENTIAL; MOUSE; MOUSE MODEL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE;

MUS;

ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; MUTATION; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84903313705     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.287     Document Type: Article

References (51)

1. Bergholz J, Xiao ZX. Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron 2012; 5: 311-322.
2. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 2011; 12: 259-265.
3. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer 2012; 13: 136-143.
4. Romano RA, Smalley K, Magraw C, Serna VA, Kurita T, Raghavan S et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012; 139: 772-782.
5. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M et al. p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci USA 2007; 104: 3255-3260.
6. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res 2009; 37: 6092-6104.
7. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18: 1487-1499.
8. Su X, Gi YJ, Chakravarti D, Chan IL, Zhang A, Xia X et al. TAp63 Is a Master Transcriptional Regulator of Lipid and Glucose Metabolism. Cell Metab 2012; 16: 511-525.
9. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin Y et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986-991.
10. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009; 11: 1451-1457.
11. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87-98.
12. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
13. Lozano G. The oncogenic roles of p53 mutants in mouse models. Current Opin Genet Dev 2007; 17: 66-70.
14. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20: 79-91.
15. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2012; 32: 2992-3000.
16. Tucci P, Agostino M, Grespi F, Marker EK, Terrinoni A, Vousden KH et al. Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 2012; 109: 15312-15317.
17. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a proinvasive secretome. Oncotarget 2011; 2: 1203-1217.
18. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2012; 32: 1203-1217.
19. Wang W, Cheng B, Miao L, Mei Y, Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis 2013; 4: e574.
20. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
21. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148: 244-258.
22. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874-1887.
23. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276: 39359-39367.
24. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
25. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
26. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
27. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246 51.
28. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2012; 32: 1252-1265.
29. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817-18826.
30. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-295.
31. Romano RA, Birkaya B, Sinha S. A functional enhancer of keratin14 is a direct transcriptional target of deltaNp63. J Invest Dermatol 2007; 127: 1175-1186.
32. Liu K, Ling S, Lin WC. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 2011; 31: 4464-4481.
33. Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF et al. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 2012; 31: 2836-2848.
34. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
35. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008; 68: 8164-8172.
36. Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G et al. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene. (epub ahead of print 10 September 2012; doi: 10.1038/onc.2012.410).
37. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G et al. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ 2008; 15: 1187-95.
38. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010; 84: 5212-5221.
39. Scheel AH, Beyer U, Agami R, Dobbelstein M. Immunofluorescence-based screening identifies germ cell associated microRNA 302 as an antagonist to p63 expression. Cell Cycle 2009; 8: 1426-1432.
40. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
41. Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev 2012; 32: 147-162.
42. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM et al. A central role for RAF-4MEK-4ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012; 2: 685-693.
43. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-1543.
44. Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M et al. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res 2010; 70: 2274-2284.
45. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
46. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
47. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-425.
48. Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 2009; 5: 64-75.
49. Waltermann A, Kartasheva NN, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene 2003; 22: 5686-5693.
50. Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 2006; 133: 1553-1563.
51. Edward M, Gillan C, Micha D, Tammi RH. Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion. Carcinogenesis 2005; 26: 1215-1223.